The early Phase 2 data and named-patient access program are positive catalysts but the stock remains a binary bet on the C-1300-02 trial outcome. With only $8.8M cash and no revenue, monitor cash runway closely, the next catalyst is additional Phase 2 data expected early 2027. The improved expense discipline is a modest positive but does not change the fundamental risk profile.
Drug in focus
INKT drug pipeline →agenT-797
● Neutral Named in this 8-K- Impact
- Phase
- Phase 2
- Time to market
- agenT-797 is not approved in any market. The most advanced program is the randomized Phase 2 ARDS trial (C-1300-02), with data expected in 2H2027. Even with positive data, additional trials and regulatory review would be needed before any potential approval, likely several years away.
- Next catalyst
- None dated
What to watchThe next hard catalyst is the U.S. dosing initiation in the randomized Phase 2 ARDS trial (C-1300-02), expected before year-end 2026, with topline data not expected until 2H2027. In the nearer term, watch for any updates on the ARPA-H BoSS program funding allocation and enrollment progress in the ongoing Phase 2 colorectal cancer trial. The company's $7.5M cash position and $1.3M quarterly operating burn suggest a financing event may be needed within 2-3 quarters to fund the ARDS trial through readout.
Price Chart
Executive Summary
MiNK Therapeutics reported Q2 2026 net loss of $3.1M ($0.62/share), improving from $4.2M ($1.06/share) in Q2 2025, with cash burn slowing to $0.7M from $9.5M to $8.8M. The key catalyst is the randomized Phase 2 trial of agenT-797 in acute lung injury showing early positive Day 28 signals, plus the first paid named-patient access program in Brazil establishing a potential revenue stream.
Key Financial Metrics
Key Facts
- Net loss improved to $3.1M in Q2 2026 from $4.2M in Q2 2025, a 26% reduction
- Cash and equivalents $8.8M as of June 30, 2026, down from $9.5M at March 31, 2026
- First patients in randomized Phase 2 trial C-1300-02 for agenT-797 in acute lung injury were alive at Day 28 with improved oxygenation and ventilator liberation
- First paid international named-patient access program established in Brazil for agenT-797
- U.S. clinical site activation underway for the Phase 2 trial; additional data expected early 2027
- EPS of -$0.62 vs -$1.06 in prior year quarter; no consensus estimate provided for Q2 2026
Financial Impact
Net loss improved by $1.1M YoY to $3.1M; cash burn of $0.7M in Q2 2026 vs $4.6M in Q1 2026; cash runway at current burn rate approximately 12 months
Risk Factors
- Cash runway limited to ~12 months at current burn rate, likely requiring additional financing
- Phase 2 data is from a small number of patients in an ongoing blinded trial, early observations may not be predictive of final results
- Named-patient access program revenue is uncertain and subject to per-patient regulatory authorization
- No approved products or revenue from commercial sales
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-347907 |
| Document: inkt-20260813.htm | 0001193125-26-347907 |
| Document: 0001193125-26-347907-index-headers.html | 0001193125-26-347907 |
| Document: 0001193125-26-347907-index.html | 0001193125-26-347907 |
| Document: 0001193125-26-347907.txt | 0001193125-26-347907 |
| 8-K Data (Synthetic) | 0001193125-26-347907 |
Track record
21 reports on INKT
5 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +16.93% at T+20 after the May 15, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $9.53 Now $9.35 −1.89% settles Dec 11
- Nov 11, 20265d ago Press Release Neutral 4/10 Entry $10.22 Now $9.35 −8.55% settles Dec 10
- Nov 2, 202614d ago Press Release Neutral 2/10 Entry $10.79 Now $9.35 −13.35% settles Dec 2
- Oct 13, 20264w ago 144 Neutral 2/10 Entry $10.23 to $10.01 Now $9.35 −8.60% ▼ −2.15% +1.46% vs SPY
- Oct 2, 20266w ago Press Release Neutral 4/10 Entry $12.44 to $10.53 Now $9.35 −24.84% ▼ −15.35% −13.55% vs SPY
- Aug 13, 202613w ago 8-K Mixed 6/10 Viewing No price data
- Aug 13, 202613w ago Press Release Mixed 6/10 Entry $11.00 to $12.00 Now $9.35 −15.00% ▲ +9.09% +10.84% vs SPY
- Aug 6, 202614w ago Press Release Bullish 6/10 Entry $11.00 to $11.23 Now $9.35 −15.00% ▲ +2.09% +1.49% vs SPY
- May 28, 202624w ago Press Release Neutral 4/10 Entry $12.20 to $11.64 Now $9.35 −23.36% ▼ −4.59% −1.45% vs SPY
- May 20, 202625w ago Press Release Neutral 4/10 Entry $10.72 to $12.14 Now $9.35 −12.78% ▲ +13.25% +12.51% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers